Company profile · free preview

AbbVie

ABBV · Updated 10/24/2026

Revenue

$61.2B

Fiscal 2025

Net income

$4.2B

Fiscal 2025

Free cash flow

$17.8B

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$61.2B$56.3B$54.3B$58.1B$56.2B
Net income$4.2B$4.3B$4.9B$11.8B$11.5B
Diluted EPS—————
Operating cash flow$19.0B$18.8B$22.8B$24.9B$22.8B
Free cash flow$17.8B$17.8B$22.1B$24.2B$22.0B
Cash$5.2B$5.5B$12.8B$9.2B$9.7B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

4.1%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $4.4BBar width = share of $108.4B operating cash flow
Operating cash flow$108.4B
Capital expenditure($4.4B)
Free cash flow$103.9B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-312026-02-20EDGAR

Ask anything about AbbVie's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies